发布求助
文献互助 智能选刊 最新文献

Future oncology最新文献

筛选
英文 中文
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission. REGAL：作为二次缓解期急性髓性白血病的维持疗法，加林派姆-S 与最佳可用疗法的对比。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-11-28 DOI: 10.1080/14796694.2024.2433935
Omer Jamy, Dragan Cicic
{"title":"REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.","authors":"Omer Jamy, Dragan Cicic","doi":"10.1080/14796694.2024.2433935","DOIUrl":"10.1080/14796694.2024.2433935","url":null,"abstract":"<p><p>Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have very poor long-term outcomes. Allogeneic stem cell transplantation (allo-SCT) can potentially cure some of these patients who are able to achieve a second or greater remission with salvage chemotherapy. Unfortunately, several barriers exist to transplantation and not all patients with r/r AML are able to proceed to allo-SCT. Therefore, novel therapies to decrease the risk of relapse in these patients are urgently needed. Wilms tumor 1 (WT1) protein has emerged as an encouraging vaccine target in AML due to its overexpression in leukemic blast cells and near absence in normal hematopoietic cells. Maintenance therapy with galinpepimut-S, a multivalent heteroclitic WT1 peptide vaccine, holds promise in early phase trials, in patients with AML by inducing a strong innate immune response against the WT1 antigen, leading to the design of this international, open-label, randomized clinical trial, named REGAL. Clinical trial registration: https://clinicaltrials.gov/study/NCT04229979. The clinical trial identifier is NCT04229979.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"73-81"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer. 一个简单的语言总结，看看larorectinib对TRK融合阳性甲状腺癌患者的疗效和安全性。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-11-29 DOI: 10.1080/14796694.2024.2415208
Steven G Waguespack, Maria E Cabanillas, Vadim Bernard-Gauthier, Nandini Assar, Gary Bloom, Rebecca Esparza, Marcia S Brose
{"title":"A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer.","authors":"Steven G Waguespack, Maria E Cabanillas, Vadim Bernard-Gauthier, Nandini Assar, Gary Bloom, Rebecca Esparza, Marcia S Brose","doi":"10.1080/14796694.2024.2415208","DOIUrl":"10.1080/14796694.2024.2415208","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"169-179"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding clinical trial jargon: helping people understand the efficacy end points used in cancer trials. 解读临床试验术语：帮助人们理解癌症试验中使用的疗效终点。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.1080/14796694.2024.2433411
Marty Henley, Gissoo DeCotiis, Hannah FitzGibbon, Eric K Singhi
{"title":"Decoding clinical trial jargon: helping people understand the efficacy end points used in cancer trials.","authors":"Marty Henley, Gissoo DeCotiis, Hannah FitzGibbon, Eric K Singhi","doi":"10.1080/14796694.2024.2433411","DOIUrl":"10.1080/14796694.2024.2433411","url":null,"abstract":"<p><p>People living with cancer should have access to clear and comprehensible treatment information to empower informed decision-making. With the increasing adoption of open access publishing and plain-language summaries, clinical trial findings in journals are becoming more accessible. However, this will only help patients if they are equipped with the relevant knowledge and understanding to make sense of these findings. This podcast highlights the need to support this aspect of health literacy by bringing together the perspectives of a patient, a patient advocate and a medical oncologist. It is accompanied by two visual, plain-language guides designed to help general audiences understand the key efficacy end points that are commonly used in trials of solid tumor treatments.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"11-14"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of APOBEC3s on the occurrence, development and prognosis of esophageal squamous cell carcinoma. APOBEC3s对食管鳞状细胞癌发生、发展及预后的影响
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-12-30 DOI: 10.1080/14796694.2024.2442300
Fan Yang, He Xiao, Xiaoyan Dai, Mingfang Xu, Mengxia Li, Jianying Bai, Nan Dai
{"title":"Impact of APOBEC3s on the occurrence, development and prognosis of esophageal squamous cell carcinoma.","authors":"Fan Yang, He Xiao, Xiaoyan Dai, Mingfang Xu, Mengxia Li, Jianying Bai, Nan Dai","doi":"10.1080/14796694.2024.2442300","DOIUrl":"https://doi.org/10.1080/14796694.2024.2442300","url":null,"abstract":"<p><p>Esophageal squamous cell carcinoma (ESCC) is a severe malignant tumor of the digestive system that poses a significant threat to human health. Despite its significance, the complex molecular mechanism regulating the occurrence and development of ESCC remain elusive. The apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) members constitute a pivotal subfamily of the APOBEC family that possess cytidine deaminase activity. In recent years, APOBEC3s (A3s) have received increasing attention due to their pivotal roles in the occurrence, development, and prognosis of ESCC. This comprehensive review systematically summarizes the latest research progress on the mechanisms of action of A3s in ESCC and discusses their impact on the development and therapeutic considerations for ESCC, with a particular focus on their potential role in immunotherapy. These insights may be of great value in continued exploration of ESCC pathogenesis and provides a theoretical foundation for the development of clinical treatment strategies for ESCC.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 1","pages":"117-125"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors. 黎巴嫩的局部晚期/转移性非小细胞肺癌：关注 ALK 酪氨酸激酶抑制剂。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-11-15 DOI: 10.1080/14796694.2024.2421737
Arafat Tfayli, Hady Ghanem, Fadi Nasr, Hampig Raphael Kourie, Georges El Hachem, Jamil Debs, Sarah Masri, Hazem I Assi, Rosario García Campelo, Joseph Kattan
{"title":"Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors.","authors":"Arafat Tfayli, Hady Ghanem, Fadi Nasr, Hampig Raphael Kourie, Georges El Hachem, Jamil Debs, Sarah Masri, Hazem I Assi, Rosario García Campelo, Joseph Kattan","doi":"10.1080/14796694.2024.2421737","DOIUrl":"10.1080/14796694.2024.2421737","url":null,"abstract":"<p><p>Treatment of non-small-cell lung cancers (NSCLC) has evolved over the last decade. According to studies, the use of targeted therapies has significantly increased the life expectancy of patients. Moreover, ALK-tyrosine kinase inhibitors (ALK-TKIs) have improved clinical outcomes. In Lebanon, translating recommendations into clinical practice remains challenging. A Lebanese expert panel of oncologists was convened to describe the management paradigm and the clinical evidence supporting the optimal use of next-generation TKIs in patients with <i>ALK</i>-rearranged NSCLC and to provide an expert overview of local challenges and recommendations for optimizing the management of advanced NSCLC in Lebanese patients. The experts agreed that these recommendations should be part of a healthcare strategy to be implemented at the national level.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"127-137"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding clinical trial jargon: helping people understand how safety and quality of life are assessed in cancer trials. 解读临床试验术语：帮助人们了解在癌症试验中如何评估安全性和生活质量。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1080/14796694.2024.2422808
Jenny Burkholder, Amy Burkholder, Gissoo DeCotiis, Hannah FitzGibbon, Pallav Mehta
{"title":"Decoding clinical trial jargon: helping people understand how safety and quality of life are assessed in cancer trials.","authors":"Jenny Burkholder, Amy Burkholder, Gissoo DeCotiis, Hannah FitzGibbon, Pallav Mehta","doi":"10.1080/14796694.2024.2422808","DOIUrl":"10.1080/14796694.2024.2422808","url":null,"abstract":"<p><p>[Figure: see text].</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"5-10"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. 达拉单抗联合来那度胺、硼替佐米和地塞米松治疗新诊断多发性骨髓瘤患者的GRIFFIN研究最终分析摘要。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-10-25 DOI: 10.1080/14796694.2024.2408909
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Shira Dinner, Katharine S Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson
{"title":"A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.","authors":"Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Shira Dinner, Katharine S Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson","doi":"10.1080/14796694.2024.2408909","DOIUrl":"10.1080/14796694.2024.2408909","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"25-49"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142498890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023). 英国晚期高级别上皮性卵巢癌治疗的当前做法：OC-NOW调查（2023年）。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI: 10.1080/14796694.2024.2424153
Christina Fotopoulou, Rebecca Bowen, Ranjit Manchanda, Agnieszka Michael, Stephen McCormack, Allan Ullmann, Anthony Wesselbaum, Bethany Levick, Rowan Miller
{"title":"Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023).","authors":"Christina Fotopoulou, Rebecca Bowen, Ranjit Manchanda, Agnieszka Michael, Stephen McCormack, Allan Ullmann, Anthony Wesselbaum, Bethany Levick, Rowan Miller","doi":"10.1080/14796694.2024.2424153","DOIUrl":"10.1080/14796694.2024.2424153","url":null,"abstract":"<p><p><b>Aim:</b> To investigate current management of advanced epithelial ovarian cancer (OC) in the UK.<b>Materials & methods:</b> A cross-sectional survey with 55 healthcare professionals involved in the care of OC patients was conducted via telephone/videoconference in March/May 2023.<b>Results:</b> Respondents reported that homologous recombination deficiency (HRD) status and brca mutations were routinely tested before planning maintenance treatment. All respondents agreed that cytoreductive surgery should be considered at first recurrence, and 65% recommended using the Descriptive Evaluation of Preoperative Selection Criteria for Operability in Recurrent Ovarian Cancer (DESKTOP) III criteria to guide secondary cytoreduction. Platinum responders typically receive poly (ADP-ribose) polymerase inhibitor maintenance therapy, regardless of HRD status.<b>Conclusion:</b> Respondents reinforce that most primary OC patients in the UK have known HRD and <i>BRCA</i> mutation status, and the role of secondary cytoreduction is increasingly recognized.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"95-103"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". 多斯他利单抗治疗原发性晚期或复发性子宫内膜癌 "的通俗语言摘要。
IF 3 4区 医学
Future oncology Pub Date : 2025-01-01 Epub Date: 2024-07-11 DOI: 10.2217/fon-2023-0940
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M Landrum, Lars C Hanker, Ashley Stuckey, Ingrid Boere, Michael A Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn McCourt, Francesco Raspagliesi, Mark S Shahin, Sarah E Gill, Bradley J Monk, Joseph Buscema, Thomas J Herzog, Larry J Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L Coleman, Matthew A Powell
{"title":"A Plain Language Summary of \"Dostarlimab for primary advanced or recurrent endometrial cancer\".","authors":"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M Landrum, Lars C Hanker, Ashley Stuckey, Ingrid Boere, Michael A Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn McCourt, Francesco Raspagliesi, Mark S Shahin, Sarah E Gill, Bradley J Monk, Joseph Buscema, Thomas J Herzog, Larry J Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L Coleman, Matthew A Powell","doi":"10.2217/fon-2023-0940","DOIUrl":"10.2217/fon-2023-0940","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"151-168"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 修正。
IF 3 4区 医学
Future oncology Pub Date : 2024-12-20 DOI: 10.1080/14796694.2024.2445908
{"title":"Correction.","authors":"","doi":"10.1080/14796694.2024.2445908","DOIUrl":"10.1080/14796694.2024.2445908","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1"},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信